Cargando…

NLRC5 germline variants as potential pharmacogenomic markers for immune checkpoint inhibitors

Detalles Bibliográficos
Autor principal:	Meng, Xiang-Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10255023/ https://www.ncbi.nlm.nih.gov/pubmed/37277194 http://dx.doi.org/10.1136/jitc-2023-007255

Ejemplares similares

Response to "NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng
por: Aizenbud, Lilach, et al.
Publicado: (2023)

Germline variants predictive of tumor mutational burden and immune checkpoint inhibitor efficacy
por: Chatrath, Ajay, et al.
Publicado: (2021)

Emerging Roles for NLRC5 in Immune Diseases
por: Wang, Jie-quan, et al.
Publicado: (2019)

NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy
por: Yoshihama, Sayuri, et al.
Publicado: (2021)

Collision of germline POLE and PMS2 variants in a young patient treated with immune checkpoint inhibitors
por: Berrino, Enrico, et al.
Publicado: (2022)

Association of Immune Checkpoint Inhibitor Therapy With Survival in Patients With Cancers With MUC16 Variants
por: Yu, Yunfang, et al.
Publicado: (2020)

Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity
por: Chin, Ik Shin, et al.
Publicado: (2022)

Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors
por: Caulfield, Jasmine I, et al.
Publicado: (2023)

NLRC5, a valuable marker for the diagnosis and prognostic assessment of hepatocellular carcinoma
por: Zhang, Xiu-Wen, et al.
Publicado: (2020)

NLRC5, at the Heart of Antigen Presentation
por: Neerincx, Andreas, et al.
Publicado: (2013)

Roles of NOD1 (NLRC1) and NOD2 (NLRC2) in innate immunity and inflammatory diseases
por: Correa, Ricardo G., et al.
Publicado: (2012)

NLRC5: A Potential Target for Central Nervous System Disorders
por: Zhang, Lu, et al.
Publicado: (2021)

NLRP3, NLRC4 and NLRC5 Gene Polymorphisms Associate with Susceptibility of Pulmonary Aspergillosis in Non-Neutropenic Patients
por: Zhong, Jinjin, et al.
Publicado: (2022)

NOD1, NOD2, and NLRC5 Receptors in Antiviral and Antimycobacterial Immunity
por: Godkowicz, Magdalena, et al.
Publicado: (2022)

Immune checkpoint inhibitors: friend or foe for osteoporosis
por: Tang, Jun
Publicado: (2023)

Neoadjuvant immune checkpoint inhibitor plus chemotherapy in rare tracheal tumors
por: Jiang, Ben‐Yuan, et al.
Publicado: (2021)

Blood pressure surveillance in cancer patients treated with immune checkpoint inhibitors
por: Tan, Sean, et al.
Publicado: (2023)

The Potential Cardiotoxicity of Immune Checkpoint Inhibitors
por: Nardi Agmon, Inbar, et al.
Publicado: (2022)

Hepatocellular carcinoma and immunotherapy: Beyond immune checkpoint inhibitors
por: Abushukair, Hassan Mohammed, et al.
Publicado: (2022)

Investigation of single and synergic effects of NLRC5 and PD-L1 variants on the risk of colorectal cancer
por: Catalano, Calogerina, et al.
Publicado: (2018)

NLRC5-CIITA Fusion Protein as an Effective Inducer of MHC-I Expression and Antitumor Immunity
por: Santharam, Madanraj Appiya, et al.
Publicado: (2023)

Activating somatic and germline TERT promoter variants in myeloid malignancies
por: Nofrini, Valeria, et al.
Publicado: (2020)

NLRC3 is a potential prognostic biomarker that is correlated with immune cell infiltration in lung adenocarcinoma
por: Zhuo, Yingchen, et al.
Publicado: (2023)

African Pharmacogenomics Consortium: Consolidating pharmacogenomics knowledge, capacity development and translation in Africa: Consolidating pharmacogenomics knowledge, capacity development and translation in Africa
por: Dandara, Collet, et al.
Publicado: (2019)

NLRC5, a promising new entry in tumor immunology
por: Chelbi, Sonia T., et al.
Publicado: (2016)

High Expression of NLRC5 Is Associated with Prognosis of Gastric Cancer
por: Li, Yuemei, et al.
Publicado: (2018)

Clinical and Molecular Correlates of NLRC5 Expression in Patients With Melanoma
por: Lv, Lei, et al.
Publicado: (2021)

Adaptive Immunity Induces Tolerance to Flagellin by Attenuating TLR5 and NLRC4-Mediated Innate Immune Responses
por: Yeoh, Beng San, et al.
Publicado: (2019)

Negative regulator NLRC3: Its potential role and regulatory mechanism in immune response and immune-related diseases
por: Sun, Deyi, et al.
Publicado: (2022)

Rechallenge in Immune Checkpoint Inhibitors Associated Renal Tubular Acidosis
por: Shah, Chintan V., et al.
Publicado: (2023)

NLRC5 elicits antitumor immunity by enhancing processing and presentation of tumor antigens to CD8(+) T lymphocytes
por: Rodriguez, Galaxia M., et al.
Publicado: (2016)

Immune recognition of Pseudomonas aeruginosa mediated by the IPAF/NLRC4 inflammasome
por: Sutterwala, Fayyaz S., et al.
Publicado: (2007)

CHEK2 Pathogenic Germline Variants in Patients With NSCLC
por: Sorscher, Steven
Publicado: (2022)

Osteonecrosis of the jaw induced by immune checkpoint inhibitors: an urgent need for attention
por: Li, Xinya, et al.
Publicado: (2023)

Effectiveness of Immune Checkpoint Inhibitors in Transplant Recipients with Progressive Multifocal Leukoencephalopathy
por: Medrano, Chloé, et al.
Publicado: (2019)

Discovery and characterization of small-molecule inhibitors of NLRP3 and NLRC4 inflammasomes
por: Sebastian-Valverde, Maria, et al.
Publicado: (2021)

NLRC5: potential novel non-invasive biomarker for predicting and reflecting the progression of IgA nephritis
por: Chen, Yusa, et al.
Publicado: (2018)

The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy
por: Shukla, Akhil, et al.
Publicado: (2021)

Gut microbiome in modulating immune checkpoint inhibitors
por: Li, Xiang, et al.
Publicado: (2022)

Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma
por: Pertesi, Maroulio, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6r162a0aeinmvukt1shpd3lrfo